Recursion amends Tempus data deal and licenses TxFM model for $12 million
On September 15, 2026, Recursion amended its master agreement with Tempus AI, extending the term to six years, removing its right to terminate for convenience, and setting annual license fees at $14 million on each of the third, fourth and fifth anniversaries, with at least $4 million payable in cash. The same day, Recursion granted Tempus a non-exclusive oncology license to its TxFM Model for a $12 million fee, paid in two $6 million installments. The filing does not state the financial effect of either agreement on Recursion's results.
Key points
- The Amendment, dated September 15, 2026, extends the Master Agreement term from five to six years and eliminates Recursion's right to terminate for convenience.
- Annual license fees are revised to $14 million on each of the third, fourth and fifth anniversaries, replacing the prior schedule of $22 million, $32 million and $42 million.
- The TxFM License Agreement, also dated September 15, 2026, grants Tempus a two-year, non-exclusive oncology license with a $12 million fee.
- The Amendment reduces the aggregate number of unique de-identified data records Recursion may access.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 21, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.